Simcere Pharmaceutical and Stanford Medicine Partner on IPF Therapy Research
Simcere Pharmaceutical has entered a research collaboration with Stanford Medicine to develop innovative therapies for Idiopathic Pulmonary Fibrosis (IPF).
Simcere Pharmaceutical | 16/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy